Share this article
Share this article
MOTHERWELL, Scotland, May 6, 2021 /PRNewswire/ Invizius Limited ( Invizius ), a biotechnology company developing treatments to suppress unwanted innate immune responses, today announces that it has closed Series A financing of £5.3 million. The financing was led by existing investors Mercia, Downing Ventures, Old College Capital, Scottish Enterprise, Solvay Ventures and new investors Calculus Capital and experienced life science entrepreneur and investor, Dr Jonathan Milner. Although already over-subscribed, the company s Series A remains open to other investors until June 2021.
Invizius will use the financing to complete a First-in-Man safety study in 2022 of its H-Guard
® Priming Solution to reduce the life-threatening inflammatory effects of haemodialysis.
disease in patients at risk of progression with and without type-2 diabetes
of chronic kidney disease in more than 20 years
In DAPA-CKD Phase III trial, Farxiga demonstrated unprecedented reduction in the risk of the composite of worsening of renal function, end-stage kidney disease and cardiovascular or renal death
AstraZeneca s Farxiga (dapagliflozin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has been approved in the US to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease (ESKD), cardiovascular (CV) death and hospitalisation for heart failure (hHF) in adults with chronic kidney disease (CKD) at risk of progression.
The approval by the Food and Drug Administration (FDA) was based on positive results from the DAPA-CKD Phase III trial. The decision follows the Priority Review designation granted by the FDA earlier this year.
Shahriar SheikhBahaei, Ph.D.
Dr. SheikhBahaei’s interest in neuroscience stemmed from the usual combination of an aptitude for science and a medical problem (stuttering) that brought him into bioscience at a young age. Dr. SheikhBahaei received his bachelor’s degree from the University of California at Berkeley, where he worked with Dr. Bob Zucker on the regulation of neurotransmitter release and Dr. John Rubenstein (UC San Francisco) on development of GABAergic neurons in basal ganglia. Dr. SheikhBahaei completed his doctoral studies in Neuroscience (2017) jointly under NIMH/NINDS – University College London (UCL) Graduate Partnership Program where he worked with Drs. Jeffrey Smith (NINDS) and Alexander Gourine (UCL). His graduate studies were on how astrocytic networks control activities of respiratory motor circuits within the brainstem. After short postdoctoral research at NINDS, Dr. SheikhBahaei became an Independent Research Scholar in 2019. In collaboration with the lab
AstraZeneca's Farxiga (dapagliflozin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has been approved in the US to reduce the risk of sustained.
GATT Technologies hemostatic sealant patch undergoes successful FIH
30 April 2021
Hemostatic sealant solutions innovator GATT Technologies has announced the successful first-in-human (FIH) of its lead product GATT-Patch â a sponge coated with a special polymer â used to resolve bleeding in a patient undergoing liver resection surgery by Radboud university medical center Nijmegen (Radboudumc). Ã
GATT Technologies offices in Nijmegen
This first patient marks the start of a multicenter clinical trial that will be conducted by three leading academic medical centers in the Netherlands: Radboudumc, The University Medical Center Groningen, who have both already treated patients in the trial, and Erasmus Medical Centrum Rotterdam Mis intending to join shortly.